Skip to main content
Premium Trial:

Request an Annual Quote

Gentel, Eprogen Ink Proteome Array Pact

NEW YORK (GenomeWeb News) – Gentel Biosciences and Eprogen today said that they will collaborate on making whole proteome microarrays for identifying new autoantibody biomarkers.

Eprogen's ProteoSep protein fractionation technology enables whole proteome microarrays to be fabricated from individual cell lines or tissue samples, such as tumor biopsies. The firms will combine that technology with Gentel's protein microarray surface chemistries.

Under the deal, partitioned whole proteome arrays will be offered for fluorescence detection on Gentel's PATH protein microarray slides and chromogenic detection on its APiX Array System. In addition, Gentel said that it will process samples on whole proteome arrays for customers through its Symphony Array Services group.

"The availability of antibodies and recombinant proteins has historically been a bottleneck in the production of protein arrays," explained Gentel President and CEO Alex Vodenlich. "Eprogen's proteome partitioning technology overcomes this bottleneck in a very unique way, and enables fabrication of whole proteome arrays customized for any researcher."

Financial and other terms of the alliance were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.